Abstract: Devices and methods for inserting an implant into skin or other tissue of a patient can include an insertion device having moveable portions that can retain, move, or otherwise control engagement and injection of a hyaluronic thread. The device can include a tubular member and a handle. The handle can include a body component coupled to the tubular member. The body component can include a passage that extends in communication with the lumen. The handle can further comprise first and second arms coupled to the body component and extending outwardly from the distal portion of the tubular member. Based on the configuration, the first and second arms can be positioned along the passage to change a cross-sectional profile of the passage and permit the device to engage or disengage the thread.
Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
Type:
Grant
Filed:
September 9, 2019
Date of Patent:
June 15, 2021
Assignee:
Allergan, Inc.
Inventors:
Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.
Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
Type:
Grant
Filed:
September 18, 2019
Date of Patent:
June 8, 2021
Assignee:
Allergan Sales, LLC
Inventors:
Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
Abstract: Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to PDGF and bispecific antibodies with antigen-binding specificities to PDGF-2 and VEGF or to PDGF and ANG-2.
Abstract: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.
Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-4,5-dihydro-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
Type:
Grant
Filed:
October 8, 2020
Date of Patent:
May 18, 2021
Assignee:
Allergan Holdings Unlimited Company
Inventors:
Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
Abstract: Provided are injectable, hyaluronic acid-based dermal filler compositions including conjugated vitamin C derivatives. The compositions provide for extended release of active vitamin C into tissue, promoting collagenesis and other benefits to skin.
Type:
Grant
Filed:
March 26, 2018
Date of Patent:
May 11, 2021
Assignee:
ALLERGAN INDUSTRIE, SAS
Inventors:
Futian Liu, Xiaojie Yu, Jessamine P. Winer-Jones, Nicholas J. Manesis, Hengli Liu, Gabriel Njikang, Athene Wan Chie Chan
Abstract: The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions which are particularly advantageous for correction of fine lines in the face.
Type:
Grant
Filed:
March 7, 2018
Date of Patent:
May 4, 2021
Assignee:
ALLERGAN INDUSTRIE, SAS
Inventors:
Gabriel N. Njikang, Xiaojie Yu, Futian Liu, Sumit Paliwal, Nicholas J. Manesis
Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
Type:
Grant
Filed:
December 10, 2018
Date of Patent:
May 4, 2021
Assignee:
ALLERGAN, INC.
Inventors:
Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
Abstract: The present invention is directed to a digestive enzyme composition comprising an enterically coated digestive enzyme product, administrable nutritional medium, and a pharmaceutically acceptable low viscosity oily ingredient. The process for the preparation of the digestive enzyme composition comprises adding an enterically coated digestive enzyme product to a administrable nutritional medium and pharmaceutically acceptable low viscosity oily ingredient. The invention further provides a method for treating a patient suffering from exocrine pancreatic insufficiency related condition comprising administering to the patient a therapeutically effective dose of the digestive enzyme composition by means of a feeding tube.
Type:
Grant
Filed:
August 4, 2014
Date of Patent:
May 4, 2021
Assignee:
Allergan Pharmaceuticals International Limited
Abstract: A skin treatment can include applying a microneedle device to a region of the skin so that microneedles of the device penetrate the stratum corneum. The arrangement of microneedles can have first microneedles with a first length and second microneedles with a second length, different from the first length. The first and second microneedles can be formed from a mixture of a polymeric material and an active agent beneficial to skin. After the device is applied to the skin, the first and second microneedles can be released below the skin surface, followed by dissolution of the first and second microneedles.
Type:
Grant
Filed:
March 30, 2020
Date of Patent:
April 27, 2021
Assignee:
ALLERGAN, INC.
Inventors:
Justin J. Schwab, Michael Augarten, Zachary Dominguez, Ethan Franklin, Edwin J. Kayda, Jason Metzner
Abstract: The present invention provides a compound, that is a 1-({halo-2-[(2-hydrocarbyl or substituted hydrocarbyl)oxy]phenyl}methyl)-(fused bicyclic nitrogen heteroaryl) carboxylic acid or an ester or sulfonamide thereof. The compound may be represented by the following formula Wherein R1, R2, R3, R4 A, X, W, Z and Y are as defined in the specification. The compounds may be administered to treat DP, FP, EP1, TP and/or EP4 receptor-mediated diseases or conditions.
Type:
Grant
Filed:
August 13, 2019
Date of Patent:
April 27, 2021
Assignee:
ALLERGAN, INC.
Inventors:
William R. Carling, Jose L. Martos, Jussi J. Kangasmetsa, Jenny W. Wang, David F. Woodward
Abstract: Synthetic methods for preparing deoxycholic acid and intermediates thereof, high purity synthetic deoxycholic acid, compositions and methods of use are provided. Also, provided are processes for the synthesis of 12-keto or 12-?-hydroxysteroids from ?-9,11-ene, 11-keto or 11-hydroxy-?-steroids. This invention is also directed to novel compounds prepared during the synthesis. This invention is also directed to the synthesis of deoxycholic acid starting from hydrocortisone.
Type:
Grant
Filed:
October 2, 2019
Date of Patent:
April 20, 2021
Assignee:
Allergan Sales, LLC
Inventors:
Robert M. Moriarty, Achampeta Rathan Prasad, John Gregory Reid, Roy A. Swaringen, Jr.
Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.
Type:
Grant
Filed:
August 5, 2019
Date of Patent:
April 13, 2021
Assignee:
Allergan, Inc.
Inventors:
Maurice Abiad, Bhas Dani, Evgenyi Shalaev
Abstract: The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5.
Type:
Grant
Filed:
July 28, 2017
Date of Patent:
March 16, 2021
Assignee:
Allergan Sales, LLC
Inventors:
Robert Emil Hodge, Jeffrey Douglas Webster, Robert M. Moriarty
Abstract: Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided. The methods comprise administering a composition comprising BoNT/DC.
Type:
Grant
Filed:
May 30, 2018
Date of Patent:
February 9, 2021
Assignee:
Allergan, Inc.
Inventors:
Birgitte P.S. Jacky, Shiazah Z. Malik, Joanne Wang, Yi Liu, Amy Brideau-Andersen, Lance E. Steward, Linh Q. Le, Edward C. Hsai
Abstract: The disclosure provides compositions for treating an ocular condition. The composition comprises a physiologically effective amount of an androgen, wherein the composition is suitable for topical administration to an eye. The disclosure further provides methods for treating an ocular condition with the disclosed compositions.
Type:
Grant
Filed:
November 28, 2016
Date of Patent:
February 2, 2021
Assignee:
ALLERGAN, INC.
Inventors:
John T. Trogden, Adnan K. Salameh, Chetan P. Pujara, Anuradha V. Gore, Jaya Giyanani
Abstract: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.